Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromePhase 3NCT00093470
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase 3 study testing Clinical Observation and Tipifarnib in people with Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Adult Acute Megakaryoblastic Leukemia, run by National Cancer Institute (NCI) at 341 sites in 3 countries.
Trial summary
This randomized phase III trial studies tipifarnib in treating patients with acute myeloid leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia
- What is being tested?
- Clinical Observation and Tipifarnib
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 144 participants
- Where
- 341 sitesin 3 countries
- Study dates
- 18 Aug 2004to 14 Apr 2015
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients eligible to enter this study must fall into one of these categories:
- Patients in first remission following primary induction failure
- Patients must have received at least two chemotherapy induction regimens
- Patients in second or subsequent remission
- Patients > 60 years old in first remission
- Patients must be in complete remission (CR) or morphologic remission (MR) by blood counts and bone marrow studies to enter the study
Show all 41Show fewer
- Confirmatory bone marrow must be performed =< 2 weeks prior to randomization
- Patients must have morphologic proof (from bone marrow aspirate, smears or touch preps of marrow biopsy) that they had AML of one of the following types prior to achievement of CR/MR
- Acute myeloblastic leukemia, minimal differentiation (French-American-British [FAB] M0)
- Acute myeloblastic leukemia without differentiation (FAB M1)
- Acute myeloblastic leukemia with maturation (FAB M2)
- Acute myelomonocytic leukemia (FAB M4)
- Acute monocytic leukemia (FAB M5)
- Acute erythroleukemia (FAB M6)
- Acute megakaryocytic leukemia (FAB M7)
- Refractory anemia with excess blasts in transformation (RAEB-T)
- AML by World Health Organization (WHO) criteria
- Acute myeloid leukemia with multilineage dysplasia
- Patients with acute promyelocytic leukemia (FAB M3) are not eligible
- Patients must be registered within 60 days of completion of therapy for the current remission; patients are eligible if they meet any of the criteria below:
- Within 60 days of remission (CR or MR) by peripheral blood counts following induction therapy or
- Within 60 days of discharge from the hospital following induction therapy or
- Within 60 days of discharge from the hospital following post-remission therapy or
- Within 60 days of recovery of blood counts following last dose of chemotherapy
- All of the patients below are eligible for study entry:
- Patients who have received consolidation therapy
- Patients who have not received any consolidation or post remission therapy
- Patients who have had an autologous stem cell transplant
- Patients who have received an allogeneic transplant (bone marrow transplant [BMT] or peripheral stem cell transplant [PSCT]) in their current remission are ineligible; patients who have had an allogeneic transplant in a previous remission and are currently in remission after subsequent relapse are eligible
- Patients with a history of extramedullary disease are eligible if they are in complete remission at the time of study entry and no longer requiring therapy for their extramedullary disease
- Patients must not be pregnant or breast-feeding; all females of childbearing potential must have a blood test or urine study < 2 weeks prior to randomization to rule out pregnancy
- Women of childbearing potential and sexually active males are strongly advised to use an accepted and effective method of contraception
- Patients must not be known to have an allergy to imidazole drugs, such as clotrimazole ketoconazole, miconazole, econazole, or terconazole; this does not include fluconazole, voriconazole, or itraconazole
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2
- Patients must not have active cardiac or pulmonary disease; but patient will be eligible if disease is medically controlled
- Patients must not have active renal disease; creatinine must be =< 1.5 x upper limit of normal
- Patients must not have active hepatic disease; total or direct bilirubin must be < 2 mg/dl
- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) must be =< 2.5 times the upper limit of normal
- Absolute neutrophil count (ANC) >= 1000/mm^3
- Platelet count >= 50,000/mm^3
- Patients must not be taking a hepatic enzyme-inducing anti-convulsant; a patient will not be eligible for the study if the patient is currently taking one of these agents and cannot be switched to a non-hepatic enzyme-inducing anti-convulsant
Who cannot join
None listed.
Trial locations and contacts
341 sites in 3 countries.
302 sites in 3 countries
United States300 sites
Summa Akron City Hospital/Cooper Cancer Center
Akron, Ohio, 44304
Akron General Medical Center
Akron, Ohio, 44307
Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
Medini, Eitan MD (UIA Investigator)
Alexandria, Minnesota, 56308
Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania, 18103
McFarland Clinic PC-William R Bliss Cancer Center
Ames, Iowa, 50010
Providence Alaska Medical Center
Anchorage, Alaska, 99508
AnMed Health Hospital
Anderson, South Carolina, 29621
Hospital District Sixth of Harper County
Anthony, Kansas, 67003
Memorial Hospital of Arkansas City
Arkansas City, Kansas, 67005
University Cancer and Blood Center LLC
Athens, Georgia, 30607
Augusta University Medical Center
Augusta, Georgia, 30912
The Medical Center of Aurora
Aurora, Colorado, 80012
Rush - Copley Medical Center
Aurora, Illinois, 60504
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland, 21287
Eastern Maine Medical Center
Bangor, Maine, 04401
Baton Rouge General Medical Center
Baton Rouge, Louisiana, 70806
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, 70809
Ochsner Health Center-Summa
Baton Rouge, Louisiana, 70809
Franciscan Saint Francis Health-Beech Grove
Beech Grove, Indiana, 46107
PeaceHealth Saint Joseph Medical Center
Bellingham, Washington, 98225
Central Vermont Medical Center/National Life Cancer Treatment
Berlin Corners, Vermont, 05602
University of Iowa Healthcare Cancer Services Quad Cities
Bettendorf, Iowa, 52722
Billings Clinic Cancer Center
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
Saint Vincent Healthcare
Billings, Montana, 59101
Montana Cancer Consortium NCORP
Billings, Montana, 59102
Saint Vincent Frontier Cancer Center
Billings, Montana, 59102
Deaconess Medical Center
Billings, Montana, 59107
University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, 35233
Saint Joseph Medical Center
Bloomington, Illinois, 61701
Boca Raton Regional Hospital
Boca Raton, Florida, 33486
Tufts Medical Center
Boston, Massachusetts, 02111
Boston Medical Center
Boston, Massachusetts, 02118
Boulder Community Hospital
Boulder, Colorado, 80301
Bozeman Deaconess Hospital
Bozeman, Montana, 59715
Internal Medicine of Bozeman
Bozeman, Montana, 59715
Harrison HealthPartners Hematology and Oncology-Bremerton
Bremerton, Washington, 98310
Roswell Park Cancer Institute
Buffalo, New York, 14263
Lahey Hospital and Medical Center
Burlington, Massachusetts, 01805
University of Vermont College of Medicine
Burlington, Vermont, 05405
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
Saint James Community Hospital and Cancer Treatment Center
Butte, Montana, 59701
Cooper Hospital University Medical Center
Camden, New Jersey, 08103
Graham Hospital Association
Canton, Illinois, 61520
Aultman Health Foundation
Canton, Ohio, 44710
Memorial Hospital
Carthage, Illinois, 62321
Sandra L Maxwell Cancer Center
Cedar City, Utah, 84720
Cancer Center of Kansas - Chanute
Chanute, Kansas, 66720
Carolinas Medical Center/Levine Cancer Institute
Charlotte, North Carolina, 28203
Hematology and Oncology Associates
Chicago, Illinois, 60611
Northwestern University
Chicago, Illinois, 60611
Jesse Brown Veterans Affairs Medical Center
Chicago, Illinois, 60612
Rush University Medical Center
Chicago, Illinois, 60612
Mercy Hospital and Medical Center
Chicago, Illinois, 60616
Swedish Covenant Hospital
Chicago, Illinois, 60625
University of Chicago Comprehensive Cancer Center
Chicago, Illinois, 60637
Marshfield Clinic-Chippewa Center
Chippewa Falls, Wisconsin, 54729
The Jewish Hospital
Cincinnati, Ohio, 45236
Case Western Reserve University
Cleveland, Ohio, 44106
MetroHealth Medical Center
Cleveland, Ohio, 44109
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa, 50325
Penrose-Saint Francis Healthcare
Colorado Springs, Colorado, 80907
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, 43210
Mercy Hospital
Coon Rapids, Minnesota, 55433
Heartland Oncology and Hematology LLP
Council Bluffs, Iowa, 51503
Geisinger Medical Center
Danville, Pennsylvania, 17822
Genesis Medical Center - East Campus
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Samaritan North Health Center
Dayton, Ohio, 45415
Decatur Memorial Hospital
Decatur, Illinois, 62526
Heartland Cancer Research NCORP
Decatur, Illinois, 62526
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - Saint Lukes Medical Center - Health One
Denver, Colorado, 80218
SCL Health Saint Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
Colorado Cancer Research Program NCORP
Denver, Colorado, 80222
Mercy Capitol
Des Moines, Iowa, 50307
Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Iowa-Wide Oncology Research Coalition NCORP
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Des Moines
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa, 50314
Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas - Dodge City
Dodge City, Kansas, 67801
Essentia Health Cancer Center
Duluth, Minnesota, 55805
Essentia Health Saint Mary's Medical Center
Duluth, Minnesota, 55805
Miller-Dwan Hospital
Duluth, Minnesota, 55805
Hematology Oncology Associates of Central New York-East Syracuse
East Syracuse, New York, 13057
Marshfield Clinic Cancer Center at Sacred Heart
Eau Claire, Wisconsin, 54701
Sacred Heart Hospital
Eau Claire, Wisconsin, 54701
Fairview-Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas - El Dorado
El Dorado, Kansas, 67042
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital of Cecil County
Elkton, Maryland, 21921
Swedish Medical Center
Englewood, Colorado, 80113
Eureka Hospital
Eureka, Illinois, 61530
NorthShore University HealthSystem-Evanston Hospital
Evanston, Illinois, 60201
Etzell, Paul S MD (UIA Investigator)
Fergus Falls, Minnesota, 56537
Swenson, Wade II, MD (UIA Investigator)
Fergus Falls, Minnesota, 56537
McLeod Regional Medical Center
Florence, South Carolina, 29506
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Broward Health Medical Center
Fort Lauderdale, Florida, 33316
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Fort Wayne Medical Oncology and Hematology Inc-Parkview
Fort Wayne, Indiana, 46845
Unity Hospital
Fridley, Minnesota, 55432
University of Florida Health Science Center - Gainesville
Gainesville, Florida, 32610
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
Illinois CancerCare-Galesburg
Galesburg, Illinois, 61401
Western Illinois Cancer Treatment Center
Galesburg, Illinois, 61401
Southeastern Medical Oncology Center-Goldsboro
Goldsboro, North Carolina, 27534
Wayne Memorial Hospital
Goldsboro, North Carolina, 27534
Wayne Radiation Oncology
Goldsboro, North Carolina, 27534
Saint Mary's Hospital and Regional Medical Center
Grand Junction, Colorado, 81501
Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana, 59405
Berdeaux, Donald MD (UIA Investigator)
Great Falls, Montana, 59405
Great Falls Clinic
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Franklin Medical Center
Greenfield, Massachusetts, 01301
Hattiesburg Clinic - Hematology/Oncology Clinic
Hattiesburg, Mississippi, 39401
Hematology and Oncology Clinic
Hattiesburg, Mississippi, 39402
Mason District Hospital
Havana, Illinois, 62644
Saint Peter's Community Hospital
Helena, Montana, 59601
Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania, 17033-0850
Hinsdale Hematology Oncology Associates Incorporated
Hinsdale, Illinois, 60521
Memorial Regional Hospital/Joe DiMaggio Children's Hospital
Hollywood, Florida, 33021
Hopedale Medical Complex - Hospital
Hopedale, Illinois, 61747
Mary Bird Perkins Cancer Center/Terrebonne General Medical Center
Houma, Louisiana, 70360
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas, 77030
Baylor Saint Luke's Medical Center
Houston, Texas, 77030
Ben Taub General Hospital
Houston, Texas, 77030
Michael E DeBakey VA Medical Center
Houston, Texas, 77030
The Methodist Hospital System
Houston, Texas, 77030
Hematology Oncology Associates of Eastern Idaho
Idaho Falls, Idaho, 83404
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Centerpoint Medical Center LLC
Independence, Missouri, 64057
Cleveland Clinic Cancer Center Independence
Independence, Ohio, 44131
Baptist MD Anderson Cancer Center
Jacksonville, Florida, 32207
Midwest Center for Hematology Oncology
Joliet, Illinois, 60432
Joliet Oncology-Hematology Associates Limited
Joliet, Illinois, 60435
Jupiter Medical Center
Jupiter, Florida, 33458
Borgess Medical Center
Kalamazoo, Michigan, 49001
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
West Michigan Cancer Center
Kalamazoo, Michigan, 49007
Kalamazoo Center for Medical Studies
Kalamazoo, Michigan, 49008
Glacier Oncology PLLC
Kalispell, Montana, 59901
Kalispell Medical Oncology
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Truman Medical Center
Kansas City, Missouri, 64108
Saint Luke's Hospital of Kansas City
Kansas City, Missouri, 64111
Saint Joseph Health Center
Kansas City, Missouri, 64114
North Kansas City Hospital
Kansas City, Missouri, 64116
Research Medical Center
Kansas City, Missouri, 64132
Kadlec Clinic Hematology and Oncology
Kennewick, Washington, 99336
Kewanee Hospital
Kewanee, Illinois, 61443
Cancer Center of Kansas-Kingman
Kingman, Kansas, 67068
Kinston Medical Specialists PA
Kinston, North Carolina, 28501
University of Tennessee - Knoxville
Knoxville, Tennessee, 37920
Community Howard Regional Health
Kokomo, Indiana, 46904
Gundersen Lutheran Medical Center
La Crosse, Wisconsin, 54601
IU Health La Porte Hospital
La Porte, Indiana, 46350
Wilford Hall Medical Center
Lackland Air Force Base, Texas, 78236
Deerpath Medical Associates
Lake Forest, Illinois, 60045
Saint Anthony Hospital
Lakewood, Colorado, 80228
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
Nevada Cancer Research Foundation CCOP
Las Vegas, Nevada, 89106
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Beebe Medical Center
Lewes, Delaware, 19958
Lewistown Hospital
Lewistown, Pennsylvania, 17044
Southwest Medical Center
Liberal, Kansas, 67901
Liberty Radiation Oncology Center
Liberty, Missouri, 64068
NorthShore Hematology Oncology-Libertyville
Libertyville, Illinois, 60048
Saint Rita's Medical Center
Lima, Ohio, 45801
Logan Regional Hospital
Logan, Utah, 84321
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Longmont United Hospital
Longmont, Colorado, 80501
McKee Medical Center
Loveland, Colorado, 80539
Mcdonough District Hospital
Macomb, Illinois, 61455
Minnesota Oncology Hematology PA-Maplewood
Maplewood, Minnesota, 55109
Marshfield Clinic
Marshfield, Wisconsin, 54449
Marshfield Medical Center
Marshfield, Wisconsin, 54449
Loyola University Medical Center
Maywood, Illinois, 60153
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida, 33136
Mount Sinai Medical Center
Miami Beach, Florida, 33140
Franciscan Saint Anthony Health-Michigan City
Michigan City, Indiana, 46360
Orange Regional Medical Center
Middletown, New York, 10940
Eastern Montana Cancer Center
Miles City, Montana, 59301
Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Abbott-Northwestern Hospital
Minneapolis, Minnesota, 55407
Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin, 54548
Saint Joseph Regional Medical Center-Mishawaka
Mishawaka, Indiana, 46545
Montana Cancer Specialists
Missoula, Montana, 59802
Saint Patrick Hospital - Community Hospital
Missoula, Montana, 59802
Community Medical Hospital
Missoula, Montana, 59804
Guardian Oncology and Center for Wellness
Missoula, Montana, 59804
West Virginia University Healthcare
Morgantown, West Virginia, 26506
Skagit Valley Hospital
Mount Vernon, Washington, 98274
The Community Hospital
Munster, Indiana, 46321
Cottonwood Hospital Medical Center
Murray, Utah, 84107
Intermountain Medical Center
Murray, Utah, 84107
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903
Louisiana State University Health Science Center
New Orleans, Louisiana, 70112
University Medical Center New Orleans
New Orleans, Louisiana, 70112
Ochsner Medical Center Jefferson
New Orleans, Louisiana, 70121
Laura and Isaac Perlmutter Cancer Center at NYU Langone
New York, New York, 10016
Weill Medical College of Cornell University
New York, New York, 10065
Christiana Care Health System-Christiana Hospital
Newark, Delaware, 19718
Cancer Center of Kansas - Newton
Newton, Kansas, 67114
Illinois Cancer Specialists-Niles
Niles, Illinois, 60714
Bromenn Regional Medical Center
Normal, Illinois, 61761
Community Cancer Center Foundation
Normal, Illinois, 61761
ProHealth Oconomowoc Memorial Hospital
Oconomowoc, Wisconsin, 53066
McKay-Dee Hospital Center
Ogden, Utah, 84403
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, 73104
Cancer Care Associates
Oklahoma City, Oklahoma, 73120
Franciscan St. James Health-Olympia Fields Campus
Olympia Fields, Illinois, 60461
Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois, 61350
Ottawa Regional Hospital and Healthcare Center
Ottawa, Illinois, 61350
Cancer Center of Kansas - Ottawa
Ottawa, Kansas, 66067
Menorah Medical Center
Overland Park, Kansas, 66209
Saint Luke's South Hospital
Overland Park, Kansas, 66213
Cancer Center of Kansas - Parsons
Parsons, Kansas, 67357
OSF Saint Francis Radiation Oncology at Pekin Cancer Treatment Center
Pekin, Illinois, 61554
Pekin Hospital
Pekin, Illinois, 61554
Methodist Medical Center of Illinois
Peoria, Illinois, 61603
Proctor Hospital
Peoria, Illinois, 61614
Illinois CancerCare-Peoria
Peoria, Illinois, 61615
OSF Saint Francis Medical Center
Peoria, Illinois, 61637
Illinois Valley Hospital
Peru, Illinois, 61354
Valley Radiation Oncology
Peru, Illinois, 61354
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104
Pennsylvania Hospital
Philadelphia, Pennsylvania, 19107
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111
Kansas City NCI Community Oncology Research Program
Prairie Village, Kansas, 66208
Cancer Center of Kansas - Pratt
Pratt, Kansas, 67124
Perry Memorial Hospital
Princeton, Illinois, 61356
Utah Valley Regional Medical Center
Provo, Utah, 84604
Saint Mary Corwin Medical Center
Pueblo, Colorado, 81004
Ascension Saint Mary's Hospital
Rhinelander, Wisconsin, 54501
Marshfield Clinic-Rice Lake Center
Rice Lake, Wisconsin, 54868
North Memorial Medical Health Center
Robbinsdale, Minnesota, 55422
Mayo Clinic
Rochester, Minnesota, 55905
William Beaumont Hospital-Royal Oak
Royal Oak, Michigan, 48073
Sarah Culbertson Memorial Hospital
Rushville, Illinois, 62681
Rutherford Hospital
Rutherfordton, North Carolina, 28139
Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Saint Cloud Hospital
Saint Cloud, Minnesota, 56303
Lakeland Hospital
Saint Joseph, Michigan, 49085
Heartland Regional Medical Center
Saint Joseph, Missouri, 64507
Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota, 55416
United Hospital
Saint Paul, Minnesota, 55102
Cancer Center of Kansas - Salina
Salina, Kansas, 67401
Intermountain Health Care
Salt Lake City, Utah, 84103
Utah Cancer Specialists-Salt Lake City
Salt Lake City, Utah, 84106
Huntsman Cancer Institute/University of Utah
Salt Lake City, Utah, 84112
LDS Hospital
Salt Lake City, Utah, 84143
Kaiser Permanente-San Diego Mission
San Diego, California, 92108
Memorial University Medical Center
Savannah, Georgia, 31404
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, 31405
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259
Mercy Hospital
Scranton, Pennsylvania, 18501
Scranton Hematology Oncology
Scranton, Pennsylvania, 18510
Harborview Medical Center
Seattle, Washington, 98104
Minor and James Medical PLLC
Seattle, Washington, 98104
Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109
Kaiser Permanente Washington
Seattle, Washington, 98112
Swedish Medical Center-First Hill
Seattle, Washington, 98122-4307
University of Washington Medical Center
Seattle, Washington, 98195
PeaceHealth United General Medical Center
Sedro-Woolley, Washington, 98284
Saint Francis Regional Medical Center
Shakopee, Minnesota, 55379
Shawnee Mission Medical Center-KCCC
Shawnee Mission, Kansas, 66204
Welch Cancer Center
Sheridan, Wyoming, 82801
Overton Brooks Veteran's Administration Medical Center
Shreveport, Louisiana, 71101
Louisiana State University Health Sciences Center Shreveport
Shreveport, Louisiana, 71103
Siouxland Regional Cancer Center
Sioux City, Iowa, 51101
Mercy Medical Center-Sioux City
Sioux City, Iowa, 51104
Saint Luke's Regional Medical Center
Sioux City, Iowa, 51104
Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota, 57104
Avera Cancer Institute
Sioux Falls, South Dakota, 57105
Avera McKennan Hospital and University Health Center
Sioux Falls, South Dakota, 57105
Medical X-Ray Center
Sioux Falls, South Dakota, 57105
Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota, 57117-5134
Edward H Kaplan MD and Associates
Skokie, Illinois, 60076
Hematology Oncology Associates of Illinois - Skokie
Skokie, Illinois, 60076
Midwest Cancer Research Group Incorporated
Skokie, Illinois, 60077
Memorial Hospital of South Bend
South Bend, Indiana, 46601
Northern Indiana Cancer Research Consortium
South Bend, Indiana, 46628
Providence Hospital-Southfield Cancer Center
Southfield, Michigan, 48075
Spartanburg Medical Center
Spartanburg, South Carolina, 29303
Cancer Care Northwest - Spokane South
Spokane, Washington, 99202
Saint Margaret's Hospital
Spring Valley, Illinois, 61362
Memorial Medical Center
Springfield, Illinois, 62781
Baystate Medical Center
Springfield, Massachusetts, 01199
Washington University School of Medicine
St Louis, Missouri, 63110
Dixie Medical Center Regional Cancer Center
St. George, Utah, 84770
About this study
Official title: A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
This randomized phase III trial studies tipifarnib in treating patients with acute myeloid leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective than observation alone in preventing the recurrence of AML.
Read the detailed description
PRIMARY OBJECTIVES:
- To compare R115777 (tipifarnib) maintenance therapy to observation only with respect to disease-free survival (DFS) in patients with AML in second or subsequent complete remission or in complete response (CR) following primary induction failure.
SECONDARY OBJECTIVES:
- To compare overall survival of patients in both arms. II. To evaluate the long-term safety and toxicity of extended administration of R115777 in AML patients in remission.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive tipifarnib orally (PO) twice daily (BID) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM B: Patients undergo observation only.
After completion of study treatment, patients are followed up for 5 years.
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation
- Being tested
- Clinical Observation, Tipifarnib
- Medical subject headings
- Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myelomonocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Erythroblastic, Acute, Anemia, Refractory, with Excess of Blasts
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical ObservationProcedure or surgery
Also called observation
Undergo observation
TipifarnibDrug
Also called R115777, Zarnestra
Given PO
| Study group | Role | What they receive |
|---|---|---|
| Arm A (tipifarnib) | Experimental | Patients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Receives: Drug: Tipifarnib |
| Arm B (clinical observation) | Other | Patients undergo observation only. Receives: Procedure: Clinical Observation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease-free Survival
Disease-free survival (DFS) is defined as the time from randomization to relapse or death without relapse.
Measured: Assessed monthly for the first 6 months then every 3 months or as clinically indicated, up to 5 years.
Secondary outcomes (1)
Overall Survival
Overall survival (OS) is defined as the time from randomization to death from any cause.
Measured: Assessed monthly for the first 6 months then every 3 months or as clinically indicated, up to 5 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Oct 2004 (estimated)
- Study start18 Aug 2004
- Primary completion20 Feb 2015
- Study completion14 Apr 2015
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeStudies of the same condition, open and under way.
- More trials run by National Cancer Institute (NCI)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 144 participants (actual)
Sponsor and investigators
- Lead sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Responsible party
- Sponsor
- Investigators
- Selina Luger, Principal investigator, ECOG-ACRIN Cancer Research Group
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00093470
- Sponsor's protocol ID
- NCI-2009-00535
- Other IDs
- NCI-2009-00535, E2902, E2902, E2902, U10CA180820, U10CA021115
- Status last verified
- Jun 2026
- First submitted
- 6 Oct 2004
- Last updated
- 14 Jul 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
- ClinicalTrials.gov ID
- NCT00093470
- Acronym / sponsor ID
- NCI-2009-00535
- Conditions
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 144 participants (actual)
- Lead sponsor
- National Cancer Institute (NCI)US National Institutes of Health
- Study start
- 18 Aug 2004 (actual)
- Primary completion
- 20 Feb 2015 (actual)
- Study completion
- 14 Apr 2015 (actual)
- First posted
- 8 Oct 2004 (estimated)
- Results
- Posted 10 Nov 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized phase III trial studies tipifarnib in treating patients with acute myeloid leukemia (AML) in remission. Tipifarnib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It is not yet known whether tipifarnib is more effective than observation alone in preventing the recurrence of AML.
Detailed description
PRIMARY OBJECTIVES:
- To compare R115777 (tipifarnib) maintenance therapy to observation only with respect to disease-free survival (DFS) in patients with AML in second or subsequent complete remission or in complete response (CR) following primary induction failure.
SECONDARY OBJECTIVES:
- To compare overall survival of patients in both arms. II. To evaluate the long-term safety and toxicity of extended administration of R115777 in AML patients in remission.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM A: Patients receive tipifarnib orally (PO) twice daily (BID) on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
ARM B: Patients undergo observation only.
After completion of study treatment, patients are followed up for 5 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A (tipifarnib) | Experimental | Drug: TipifarnibPatients receive tipifarnib PO BID on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. |
| Arm B (clinical observation) | Other | Procedure: Clinical ObservationPatients undergo observation only. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (41 listed)
- Patients eligible to enter this study must fall into one of these categories:
- Patients must be in complete remission (CR) or morphologic remission (MR) by blood counts and bone marrow studies to enter the study
- Patients must have morphologic proof (from bone marrow aspirate, smears or touch preps of marrow biopsy) that they had AML of one of the following types prior to achievement of CR/MR
- Patients with acute promyelocytic leukemia (FAB M3) are not eligible
- Patients must be registered within 60 days of completion of therapy for the current remission; patients are eligible if they meet any of the criteria below:
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical ObservationAlso: observationUndergo observation | Procedure or surgery | Arm B (clinical observation) |
| TipifarnibAlso: R115777, ZarnestraGiven PO | Drug | Arm A (tipifarnib) |
Primary outcome
Disease-free Survival
Time frame: Assessed monthly for the first 6 months then every 3 months or as clinically indicated, up to 5 years.
Disease-free survival (DFS) is defined as the time from randomization to relapse or death without relapse.
1 secondary outcome
Overall Survival
Time frame: Assessed monthly for the first 6 months then every 3 months or as clinically indicated, up to 5 years.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jul 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data Archive.Link provided by the sponsor.
Related trials for Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Active, not recruitingPhase 2
Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Leukemia in Remission, or Chronic Myelomonocytic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 2
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Not yet recruitingPhase 2
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
RecruitingPhase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Selina Luger principal investigator
ECOG-ACRIN Cancer Research Group
341 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Clinical Observation and Tipifarnib in people with Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome and Adult Acute Megakaryoblastic Leukemia, run by National Cancer Institute (NCI) at 341 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 41 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 341 sites in United States, Israel, Peru. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 10 Nov 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease-free Survival (time frame: Assessed monthly for the first 6 months then every 3 months or as clinically indicated, up to 5 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jul 2026.